Wilding JPH - Search Results

1

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.

Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS. Zelniker TA, et al. Among authors: wilding jph. Lancet. 2019 Jan 5;393(10166):31-39. doi: 10.1016/S0140-6736(18)32590-X. Epub 2018 Nov 10. Lancet. 2019. PMID: 30424892

2

PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.

Wilding JP. Wilding JP. Diabetes Obes Metab. 2012 Nov;14(11):973-82. doi: 10.1111/j.1463-1326.2012.01601.x. Epub 2012 Apr 23. Diabetes Obes Metab. 2012. PMID: 22443197 Review.

3

The importance of weight management in type 2 diabetes mellitus.

Wilding JP. Wilding JP. Int J Clin Pract. 2014 Jun;68(6):682-91. doi: 10.1111/ijcp.12384. Epub 2014 Feb 18. Int J Clin Pract. 2014. PMID: 24548654 Free PMC article.

4

The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors.

Wilding JP. Wilding JP. Metabolism. 2014 Oct;63(10):1228-37. doi: 10.1016/j.metabol.2014.06.018. Epub 2014 Jul 2. Metabolism. 2014. PMID: 25104103 Free article. Review.

5

Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus.

Wilding JP, Blonde L, Leiter LA, Cerdas S, Tong C, Yee J, Meininger G. Wilding JP, et al. J Diabetes Complications. 2015 Apr;29(3):438-44. doi: 10.1016/j.jdiacomp.2014.12.016. Epub 2014 Dec 31. J Diabetes Complications. 2015. PMID: 25660137 Free article. Clinical Trial.

6

Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes.

Cefalu WT, Stenlöf K, Leiter LA, Wilding JP, Blonde L, Polidori D, Xie J, Sullivan D, Usiskin K, Canovatchel W, Meininger G. Cefalu WT, et al. Diabetologia. 2015 Jun;58(6):1183-7. doi: 10.1007/s00125-015-3547-2. Epub 2015 Mar 27. Diabetologia. 2015. PMID: 25813214 Free PMC article. Clinical Trial.

7

SGLT2 inhibitors: providing cardiovascular protection in type 2 diabetes?

Wilding J. Wilding J. Lancet Diabetes Endocrinol. 2016 May;4(5):379-81. doi: 10.1016/S2213-8587(16)00084-X. Epub 2016 Mar 18. Lancet Diabetes Endocrinol. 2016. PMID: 27009624 No abstract available.

8

Positioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm.

Wilding JP, Rajeev SP, DeFronzo RA. Wilding JP, et al. Diabetes Care. 2016 Aug;39 Suppl 2:S154-64. doi: 10.2337/dcS15-3005. Diabetes Care. 2016. PMID: 27440828 Review.

9

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.

le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, Ortiz RV, Wilding JPH, Skjøth TV, Manning LS, Pi-Sunyer X; SCALE Obesity Prediabetes NN8022-1839 Study Group. le Roux CW, et al. Among authors: wilding jph. Lancet. 2017 Apr 8;389(10077):1399-1409. doi: 10.1016/S0140-6736(17)30069-7. Epub 2017 Feb 23. Lancet. 2017. PMID: 28237263 Free article. Clinical Trial.

10

Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus.

Budoff MJ, Wilding JPH. Budoff MJ, et al. Among authors: wilding jph. Int J Clin Pract. 2017 May;71(5):e12948. doi: 10.1111/ijcp.12948. Int J Clin Pract. 2017. PMID: 28508457 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

335 results

Search Page

Filters